New York, New York 10065

  • Unspecified Adult Solid Tumor, Protocol Specific


RATIONALE: Diagnostic procedures, such as CT scans, may help measure solid tumors and assess a patient's response to treatment. PURPOSE: This clinical trial is comparing two methods of measuring tumors by CT scan in patients with solid tumors.

Study summary:

OBJECTIVES: Primary - To compare the volumetric response achieved using semi-automated computer techniques with the unidimensional (RECIST) and bidimensional (WHO) criteria as part of clinical trials running at MSKCC, testing new agents for different types of solid tumors. Secondary - To assess the effect of CT slice thickness on 3D, 2D, and 1D size measurements. - To study variability (reproducibility) of the three segmentation algorithms developed for liver, lung, and metastatic lymphadenopathy. - To compare computer algorithm variability against intra- and inter-radiologist variability. - To validate each algorithm's accuracy by comparing measurements obtained from the computer algorithm with the "Gold Standard" radiologist reading. OUTLINE: The research project coordinator (RPC) is notified when a patient is scheduled for CT scan. The RPC forwards this information to the CT scan technician performing the CT scan on the patient per the therapeutic protocol. CT images of the patient reconstructed at different slice thicknesses are electronically transferred from the hospital PACS to the research PACS server where patient identification information is de-identified. The images stored in the research PACS are accessed by the research workstations where image processing and analysis is performed. Segmentation algorithms are used to segment tumors, measure tumor sizes, and size changes in the course of chemotherapy. The variability of the algorithm and effects of CT image slice thickness on the size measurements is also studied.


DISEASE CHARACTERISTICS: - Registered and being treated on 1 of the following therapeutic protocols: - MSKCC-06-043 - MSKCC-07-052 - MSKCC-07-057 - Must have at least 1 measurable lesion* as per RECIST criteria situated in lung, liver, or lymph node meeting RECIST criteria noted on a baseline CT scan - Baseline and at least 1 follow-up CT scan obtained at an MSKCC facility NOTE: *The measurable lesion is metastatic in the liver, lung, or lymph node and algorithms do not distinguish between primary and metastatic disease, therefore, a primary lesion (e.g., in the liver or lung) may also be assessed PATIENT CHARACTERISTICS: - Not pregnant or nursing PRIOR CONCURRENT THERAPY: - See Disease Characteristics



Primary Contact:

Principal Investigator
Binsheng Zhao, PhD, DSc
Memorial Sloan-Kettering Cancer Center

Backup Contact:


Location Contact:

New York, New York 10065
United States

Binsheng Zhao, PhD, DSc
Phone: 212-639-8759

Site Status: Recruiting

Data Source:

Date Processed: December 08, 2022

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.